+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Effect of rosiglitazone on inflammatory cytokines and oxidative stress after intensive insulin therapy in patients with newly diagnosed type 2 diabetes



Effect of rosiglitazone on inflammatory cytokines and oxidative stress after intensive insulin therapy in patients with newly diagnosed type 2 diabetes



Diabetology and Metabolic Syndrome 11: 35



To evaluate the effect of insulin sensitizer on inflammatory cytokines and oxidative stress in patients with newly diagnosed type 2 diabetes mellitus (T2DM). After intensive insulin therapy, patients with newly diagnosed T2DM were continuously treated with either insulin sensitizer or insulin for 48 weeks, and then their inflammatory cytokine and oxidative stress levels were measured. Tumor necrosis factor alpha (TNF-α), interleukin (IL)-6, hypersensitive C reactive protein (hs-CRP), malondialdehyde (MDA), and 8-iso-prostaglandin F2α (8-iso-PGF) levels of the rosiglitazone (RSG) group and the rosiglitazone combined with metformin (RSG + metformin) group were significantly reduced after the treatments (P < 0.05). Hs-CRP, MDA, and 8-iso-PGF levels of the metformin group were significantly reduced after the treatments (P < 0.05). Superoxide dismutase (SOD) and total antioxidant capacity (TAC) were significantly increased after the treatments in all three groups (P < 0.05 and P < 0.01). Early application of insulin sensitizers improved inflammation and oxidative stress in patients with newly diagnosed T2DM.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 066770076

Download citation: RISBibTeXText

PMID: 31073335

DOI: 10.1186/s13098-019-0432-z


Related references

Effects of rosiglitazone on inflammatory reaction and insulin resistance in obese patients with newly diagnosed type 2 diabetes. Nan Fang Yi Ke Da Xue Xue Bao 28(6): 1050-1051, 2008

Effect of short-term intensive treatment with insulin pump on beta cell function and the mechanism of oxidative stress in newly diagnosed type 2 diabetic patients. Nan Fang Yi Ke Da Xue Xue Bao 27(12): 1878-1879, 2007

The effect of short-term intensive insulin therapy on circulating T cell subpopulations in patients with newly diagnosed type 2 diabetes mellitus. Diabetes Research and Clinical Practice 2019, 2019

Indications for a favourable effect of intensive insulin therapy for newly-diagnosed type 2 diabetes. Nederlands Tijdschrift Voor Geneeskunde 152(44): 2378-2380, 2008

Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 371(9626): 1753-1760, 2008

A 2-year pilot trial of continuous subcutaneous insulin infusion versus intensive insulin therapy in patients with newly diagnosed type 1 diabetes (IMDIAB 8). Diabetes Technology and Therapeutics 5(6): 965-974, 2004

Effects of intensive insulin therapy upon pancreatic β cell function in patients newly diagnosed with type II diabetes. International Journal of Clinical and Experimental Medicine 8(1): 1391-1395, 2015

The Effect of Early Intensive Insulin Therapy on Body Fat Distribution and β-Cell Function in Newly Diagnosed Type 2 Diabetes. Endocrine Research 2013, 2013

Effects of short-term therapy with different insulin secretagogues on glucose metabolism, lipid parameters and oxidative stress in newly diagnosed Type 2 Diabetes Mellitus. Diabetes Research and Clinical Practice 88(1): 42-47, 2010

Effect of intensive insulin therapy on first-phase insulin secretion in newly diagnosed type 2 diabetic patients with a family history of the disease. Experimental and Therapeutic Medicine 9(2): 612-618, 2015

Intensive insulin therapy in newly diagnosed type 2 diabetes. Lancet 371(9626): 1725-1726, 2008

Insulin requirement profiles of short-term intensive insulin therapy in patients with newly diagnosed type 2 diabetes and its association with long-term glycemic remission. Diabetes Research and Clinical Practice 108(2): 250-257, 2015

Increased 1,5-anhydroglucitol predicts glycemic remission in patients with newly diagnosed type 2 diabetes treated with short-term intensive insulin therapy. Diabetes Technology and Therapeutics 14(9): 756-761, 2012

Short-term continuous subcutaneous insulin infusion combined with insulin sensitizers rosiglitazone, metformin, or antioxidant α-lipoic acid in patients with newly diagnosed type 2 diabetes mellitus. Diabetes Technology and Therapeutics 15(10): 859-869, 2014

Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care 27(5): 1028-1032, 2004